Sonnet BioTherapeutics Holdings EBIT

The latest EBIT for SONN is $-16M as of September 2025. That compares with $-12M in the prior-year period — down 34.0% year over year. That is below the Consumer Staples sector average of $730B. Investors often review this figure alongside Sonnet BioTherapeutics Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, SONN's EBIT moved from $-12M to $-16M — a 34.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Sonnet BioTherapeutics Holdings's operating scale or balance-sheet position.

Against Consumer Staples companies, SONN currently prints $-16M for EBIT, while the sector average sits near $730B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Sonnet BioTherapeutics Holdings's growth, margins, and balance sheet.

A EBIT figure of $-16M for SONN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Consumer Staples average is about $730B. Explore the charts below for those layers of context.

After noting SONN's EBIT ($-16M), review year-over-year change from $-12M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.